Home » Pipeline
Pipeline
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| COVID-19 Trials and Actions | |||
| OncoSec Medical | CORVax12 | DNA-encodable vaccine against SARS-CoV-2 | IND approved by the FDA |
| Equillium | itolizumab | hospitalized COVID-19 patients with acute respiratory distress syndrome (ARDS) | IND approved by FDA for phase 3 trial |
| Symvivo Corporation | bacTRL-spike oral vaccine | prevention of COVID-19 | first patient dosed in phase 1 trial |
| RevImmune | CYT107 (recombinant human Interleukin-7) | patients critically ill with COVID-19 | patient enrollment initiated in the U.S. in phase 2 trial |
| Humanigen | lenzilumab | prevention of cytokine storm in hospitalized patients with COVID-19 | first patient dosed in phase 3 trial |
| Other Trials and Actions | |||
| enGene | EG-70 | Bacille Calmette-Guerin (BCG)-unresponsive nonmuscle-invasive bladder cancer | IND approved by the FDA |
| InnoCare Pharma | orelabrutinib | multiple sclerosis | IND approved by the FDA |
| Neuraly | NLY01 | Alzheimer’s disease | IND approved by the FDA |
| OliX Pharmaceuticals | OLX10010 | adjunct therapy to reduce the recurrence of hypertrophic scars after scar revision surgery | IND approved by the FDA |
| TaiGen Biotechnology | TG-1000 | influenza A and B | IND approved by the FDA |
| Aligos Therapeutics | ALG-000184 | chronic hepatitis B virus | first patient dosed in phase 1a/1b trial |
| BiomX | BX002 | inflammatory bowel disease | first patient dosed in phase 1a trial |
| Synlogic | SYNB8802 | enteric hyperoxaluria | first patient dosed in phase 1 trial |
| MindMed | LSD microdose and experiential doses | anxiety disorders | completion of phase 1 trial |
| Q32 Bio | ADX-914 | autoimmune diseases | first patient dosed in phase 1 trial |
| ADC Therapeutics | camidanlumab tesirine (ADCT-301) in combination with pembrolizumab | select advanced solid tumors | first patients dosed in combination arm of phase 1b trial |
| Gritstone Oncology | GRANITE and SLATE (neoantigen-based immunotherapies) | historically cold (or non-immunogenic) tumor types | first patients dosed in phase 2 expansion cohorts of phase 1/2 trials |
| Rubius Therapeutics | RTX-240 | acute myeloid leukemia | first patient dosed in phase 1/2 trial |
| Novus Therapeutics | AT-1501 | amyotrophic lateral sclerosis | first patient enrolled in phase 2a trial |
| AIVITA Biomedical | AV-GBM-1 | glioblastoma | patient dosing complete in phase 2 trial |
| Amino Technology | PalinGen Flow | adults with chronic ulcers of the lower extremities due to venous stasis or diabetic etiologies | initiation of phase 2 trial |
| NanOlogy | NanoPac (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection | prostate cancer | first patient enrolled in phase 2 trial |
| PolyActiva | latanoprost-free-acid sustained-release ocular implant | glaucoma | initiation of phase 2 trial in Australia |
| Enlivix | Allocetra | sepsis | approval received from the Israeli Ministry of Health for a phase 2b trial |
| Pfizer | vupanorsen (AKCEA-ANGPTL3-LRx) | patients with elevated nonhigh-density lipoprotein cholesterol (nonHDL-C) and triglycerides | initiation of phase 2b trial |
| Asieris Pharmaceuticals | APL-1202 | nonmuscle-invasive bladder cancer | approval granted by the Center for Drug Evaluation of the China National Medical Products Administration to initiate phase 3 trial |
| Cerevel Therapeutics | tavapadon | Parkinson’s disease | first patients dosed in three phase 3 trials |
| Concert Pharmaceuticals | CTP-543 | moderate-to-severe alopecia areata | initiation of phase 3 trial |
| Daiichi Sankyo AstraZeneca |
Enhertu (fam-trastuzumab deruxtecan-nxki) | adjuvant therapy in patients with HER2-positive early breast cancer with high risk of disease recurrence who have residual invasive disease in the breast or axillary lymph nodes after receiving neo-adjuvant therapy | initiation of phase 3 trial |
| GW Pharmaceuticals Greenwich Biosciences |
nabiximols | multiple sclerosis-associated spasticity | initiation of phase 3 trial |
| LianBio | infigratinib | locally advanced or metastatic unresectable cholangiocarcinoma with FGFR2 gene fusions | approval granted by the Center for Drug Evaluation of the China National Medical Products Administration to initiate phase 3 trial |
| Logic Bio | LB-001 | methylmalonic acidemia | Fast-Track designation granted by the FDA |
| Rafael Pharmaceuticals | CPI-613 (devimistat) | soft tissue sarcoma | Orphan Drug designation granted by the FDA |
| Boston Scientific | Ranger drug-coated balloon | patients with peripheral artery disease in the superficial femoral artery and proximal popliteal artery | approved by the FDA |
| Chiesi, USA | Bronchitol (mannitol) inhalation powder | add-on maintenance therapy to improve pulmonary function in cystic fibrosis patients 18 years of age and older | approved by the FDA |
Upcoming Events
-
24May
-
25May
-
28Jun
-
16Oct
